"I think the A to Z trial pushed the dose of a good drug beyond its safe limits, " says Steven Nissen, a cardiologist at the Cleveland Clinic who wrote a blistering commentary about A to Z in JAMA. "The study falls far short of acceptable scientific evidence, " Nissen says.
FORBES: Cholesterol Study Poses Dangers For Merck